RANKL blockade attenuates MASH by remodeling the hepatic immune microenvironment
Frontiers in Immunology · 05.11.2026 · 17
DOI: 10.3389/fimmu.2026.1901751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 05.11.2026. Verfasst von Junxue Wang und 6 weiteren Autor:innen. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of chronic liver disease worldwide and is largely driven by chronic inflammation and hepatic immune dysregulation. The receptor activator of nuclear factor-κB ligand (RANKL) is a master regulator of bone metabolism with emerging immunomodulatory functions. Although growing evidence links the RANK-RANKL-OPG axis to MASH pathophysiology, whether RANKL blockade attenuates MASH development remains unclear. This study therefore investigated the effects and underlying mechanisms of RANKL blockade in a mouse model of MASH.
Methods
Male mice were fed a choline-deficient high-fat diet (CDHFD) for 16 weeks to induce MASH and were treated with the RANKL-neutralizing antibody IK22/5 (1, 4, or 8 mg/kg) or an IgG control. Metabolic parameters, liver histology, and biochemical markers were assessed. Hepatic immune-cell infiltration was analyzed using CIBERSORT-based deconvolution, and immune populations were characterized by flow cytometry. Transcriptomic profiling identified RANKL-regulated genes, followed by cross-species analysis using human MASH datasets.
Results
RANKL blockade dose-responsively improved glucose tolerance, hepatic steatosis, inflammation, and fibrosis. Transcriptomic analysis identified 48 genes that were dysregulated in MASH but reversed by RANKL blockade; these genes were enriched in lipid metabolism, immune regulation, and fibrosis pathways. Immune profiling revealed broad remodeling of the hepatic immune microenvironment: IK22/5 reduced CD11b high F4/80 + monocyte-derived macrophages, CD86 + M1-like macrophages, CD3 - NK1.1 + NK cells, and CD3 + NK1.1 + CD4 - CD8 - NKT-like cells, while increasing γδ T cells and preserving CD11b int F4/80 + Tim4 + Kupffer cells. Immunofluorescence showed that RANKL blockade significantly reduced hepatic CD74 + F4/80 + macrophages, together with decreased expression of other lipid-associated macrophage markers.
Conclusions
Overall, these findings indicate that RANKL blockade attenuated MASH development and support RANKL as a potential immune–metabolic regulator, providing a preclinical rationale for further evaluation of RANKL-targeted strategies in clinically relevant models.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Yang, N., Li, H., Dan, S., Guo, H., Zha, K., & Xia, F. (2026). RANKL blockade attenuates MASH by remodeling the hepatic immune microenvironment. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1901751
Vancouver
Wang J, Yang N, Li H, Dan S, Guo H, Zha K, et al. RANKL blockade attenuates MASH by remodeling the hepatic immune microenvironment. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1901751
BibTeX
@article{Wang2026,
author = {Wang, Junxue and Yang, Ningjia and Li, Huixia and Dan, Sijia and Guo, Hui and Zha, Kexi and Xia, Fangzhen},
title = {RANKL blockade attenuates MASH by remodeling the hepatic immune microenvironment},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1901751}
}
EUVIMED